Search
Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL] study
double-blind, multicenter study
654 patients who required angiography
luminal narrowing of >= 20% in at least one coronary artery
Patients randomized to:
- pravastatin 40 mg or
- atorvastatin 80 mg daily
Baseline LDL cholesterol levels 150 mg/dL
Results:
1) reduction of LDL cholesterol to
- 110 mg/dL in pravastatin group
- 79 mg/dL in atorvastatin group
2) serum C-reactive protein baseline of 2.9 mg/dL, diminished
- 5.2% in pravastatin group
- 36% in atorvastatin group
3) atheroma progression at 18 months, measured by intravascular ultrasound was less in the atorvastatin group compared to the pravastatin group
4) lower LDL cholesterol & lower CRP levels independently associated less progression of atheroma volume
Related
PROVE-IT study
General
clinical trial
References
- Journal Watch 24(9):69-70, 2004
Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA,
Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN;
REVERSAL Investigators.
Effect of intensive compared with moderate lipid-lowering
therapy on progression of coronary atherosclerosis: a
randomized controlled trial.
JAMA. 2004 Mar 3;291(9):1071-80.
PMID: 14996776
- Journal Watch 25(3):21, 2005
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH,
Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation
and Infection Therapy-Thrombolysis in Myocardial Infarction 22
(PROVE IT-TIMI 22) Investigators.
C-reactive protein levels and outcomes after statin therapy.
N Engl J Med. 2005 Jan 6;352(1):20-8.
PMID: 15635109